← Back to Clinical Trials
Recruiting NCT05934994

Contribution of MUltiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Bone Lesion
Sponsor Central Hospital, Nancy, France
Study Type INTERVENTIONAL
Phase N/A
Enrollment 68
Sex ALL
Min Age 18 Years
Max Age 90 Years
Start Date 2023-09-11
Completion 2025-12-10
Interventions
Bone scan

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The hypothesis of the study is that non-invasive Single photon emission computed tomography (SPECT-CT) bone scintigraphy makes it possible to better characterize solitary bone lesions, in particular the exclusion of their malignancy in order to avoid unnecessary biopsy and possible complications for the patient.

Eligibility Criteria

Inclusion Criteria: * Person, having received complete information on the organization of the research and having signed the informed consent and: * Age ≥ 18 years old. * Having read and understood the information document. * Affiliated to a social security scheme. * Patient with an indeterminate solitary bone lesion on conventional imaging, for which an indication for biopsy +/- excision is planned. Exclusion Criteria: * Pregnant woman or woman of childbearing age and without contraceptive means or nursing mother. * Unstable medical condition and/or inability to remain still during recordings. * Known allergy to one of the components of the radiopharmaceutical technetium-99m-Technescan HDP (product required to perform the bone scan). * Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code. * Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under articles L. 3212-1, L. 3213-1

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}